ELISA Analyzers Market to Reach USD 1.6 Billion by 2036 from USD 0.8 Billion in 2025, Expanding at 6.7% CAGR

The global ELISA analyzers market was valued at USD 0.8 billion in 2025 and is projected to reach USD 1.6 billion by 2036, expanding at a CAGR of 6.7% from 2026 to 2036. Increasing demand for accurate diagnostic testing, rising incidence of infectious and chronic diseases, and growing adoption of laboratory automation are supporting the development of the market. Expansion of healthcare infrastructure and increasing investments in life sciences research are also expected to create new opportunities for ELISA analyzer manufacturers.

ELISA analyzers are laboratory instruments designed to automate enzyme-linked immunosorbent assay testing. ELISA is widely used to detect and quantify antibodies, antigens, proteins, hormones, and other biological substances. Automated analyzers can improve testing accuracy, reduce manual errors, increase sample processing capacity, and shorten turnaround times.

These systems are used across hospitals, diagnostic laboratories, pharmaceutical and biotechnology companies, academic and research institutions, contract research organizations, and food-testing laboratories. Increasing testing volumes are encouraging laboratories to transition from manual workflows toward automated platforms capable of processing multiple samples efficiently.

Technological advancement is further transforming the ELISA analyzers industry. Manufacturers are introducing systems with higher throughput, improved software integration, laboratory information system connectivity, user-friendly interfaces, and automated sample processing. Compact analyzers are also gaining attention among small and medium-sized laboratories because they can provide automated testing capabilities while requiring comparatively lower infrastructure investment.

Despite these opportunities, high upfront costs, maintenance requirements, regulatory compliance, and competition from alternative immunoassay technologies may limit market expansion. Nevertheless, continued investment in laboratory automation, diagnostic infrastructure, and life sciences research is expected to sustain demand for ELISA analyzers through 2036.

→Discover Market Opportunities - Request Your Sample Copy Now: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=85919

Rising Adoption of Automated Diagnostic Testing Strengthens ELISA Analyzer Demand

The growing adoption of automated diagnostic testing in clinical laboratories is a major factor driving the ELISA analyzers market. Laboratories are facing increasing sample volumes and growing demand for rapid and reliable diagnostic results. Automation enables laboratories to streamline repetitive testing procedures while improving consistency and operational efficiency.

Automated ELISA analyzers can minimize manual assay steps involving sample dispensing, incubation, washing, plate reading, and result analysis. Integrating these processes into automated workflows can reduce human intervention and the risk of manual errors while allowing laboratories to process more samples within shorter timeframes.

The increasing focus on laboratory quality and standardization is further supporting the adoption of automated diagnostic equipment. The Clinical Laboratory Improvement Amendments program administered by the Centers for Disease Control and Prevention focuses on quality standards for laboratories conducting testing on human specimens. Greater emphasis on standardized and repeatable diagnostic processes is encouraging laboratories to invest in technologies capable of delivering consistent results.

Large hospitals, reference laboratories, and diagnostic networks are particularly suited to automated ELISA workstations because of their high testing volumes. As healthcare systems increasingly prioritize operational efficiency and faster turnaround times, automated immunoassay platforms are expected to gain further adoption.

Increasing Burden of Infectious and Chronic Diseases Expanding ELISA Testing

The rising incidence of infectious and chronic diseases is increasing the need for accurate and timely diagnostic testing and, consequently, supporting demand for ELISA analyzers. ELISA technology offers sensitivity, specificity, and the ability to process large numbers of samples, making it useful across a broad range of diagnostic applications.

ELISA-based testing is used for infectious disease detection, autoimmune disease assessment, cancer-related biomarker analysis, hormonal disorders, and metabolic disorders. As disease burdens increase, healthcare providers require dependable laboratory systems capable of supporting screening, diagnosis, monitoring, and research activities.

According to the World Health Organization, noncommunicable diseases account for approximately 43 million deaths annually. Cardiovascular diseases contribute about 19 million deaths, cancers approximately 10 million, chronic respiratory diseases around 4 million, and diabetes more than 2 million deaths annually. WHO also estimates that approximately 18 million people die from noncommunicable diseases before the age of 70 each year, with 82% of these premature deaths occurring in low- and middle-income countries.

India is also strengthening its capacity to address chronic diseases. According to the Ministry of Health and Family Welfare, India's National Programme for Prevention and Control of Non-Communicable Diseases had enrolled more than 76.94 crore beneficiaries and was managing more than 9.36 crore patients undergoing treatment for hypertension and diabetes through its digital platform.

Increasing disease screening and monitoring requirements are therefore encouraging healthcare systems to expand laboratory capacity. This trend is expected to support demand for automated ELISA analyzers in clinical and diagnostic settings.

Expanding Healthcare and Diagnostic Infrastructure Creates Growth Opportunities

Expansion of healthcare and diagnostic infrastructure in emerging economies represents a significant opportunity for the ELISA analyzers market. Governments are strengthening primary healthcare networks, expanding diagnostic services, and improving access to laboratory testing in underserved areas.

ELISA analyzers can support these initiatives by enabling high-volume testing for infectious diseases, chronic disease biomarkers, and other diagnostic applications. Automated systems can also improve workflow efficiency in facilities where testing volumes are increasing.

India provides an example of expanding primary healthcare infrastructure. According to the Ministry of Health and Family Welfare, 182,944 Ayushman Arogya Mandirs were functional across the country as of December 31, 2025. These facilities are strengthening access to primary healthcare services, including diagnostic capabilities.

The Ministry has stated that Ayushman Arogya Mandirs operating through Primary Health Centres provide 172 essential drugs and 63 diagnostic services, while Sub Health Centre-based institutions provide 106 drugs and 14 diagnostic services. Such expansion reflects the broader strengthening of diagnostic capacity within the country's primary healthcare system.

The World Health Organization has also highlighted India's efforts to expand integrated diagnostic services through primary healthcare reforms. Greater availability of laboratory diagnostics, screening, essential medicines, and referral systems can increase the need for automated laboratory equipment.

Similar healthcare infrastructure investments across Asia Pacific, Latin America, and the Middle East & Africa are expected to create opportunities for ELISA analyzer manufacturers. As emerging healthcare systems improve laboratory capacity and expand diagnostic coverage, demand for reliable and scalable immunoassay platforms is likely to increase.

Automated ELISA Workstations Hold Major Market Share

Automated ELISA workstations dominated the global ELISA analyzers market in 2025, accounting for approximately 67.2% of total market revenue. These systems are capable of handling large numbers of samples across multiple plates while performing several assay steps through integrated automated workflows.

Automated ELISA workstations can combine sample dispensing, incubation, plate washing, reading, and result analysis within a coordinated system. This reduces manual intervention and can improve laboratory productivity, consistency, and turnaround times.

The segment is particularly relevant to large hospitals, reference laboratories, blood banks, and research organizations that process substantial numbers of samples. Growing investment in laboratory infrastructure and increasing emphasis on quality-assured diagnostic services are further supporting adoption.

Healthcare infrastructure investment in Europe is also contributing to laboratory modernization. The European Commission's EU4Health Programme for 2021–2027 allocates approximately €5.3 billion, equivalent to around USD 6.1 billion, to support healthcare systems within EU member states, including areas associated with diagnostic preparedness and healthcare infrastructure.

Disease surveillance initiatives are also increasing the need for standardized laboratory testing. The European Centre for Disease Prevention and Control has established mechanisms for monitoring serious cross-border infectious disease threats, while laboratory networking initiatives such as RISLNET are strengthening diagnostic and surveillance capabilities across African Union member states.

Increasing emphasis on standardized testing, laboratory automation, and integrated diagnostic networks is therefore expected to support continued demand for automated ELISA workstations.

→Explore Strategies & Trends - Request Full Report Access – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=85919

North America Leads ELISA Analyzers Market

North America dominated the global ELISA analyzers market in 2025, accounting for approximately 38.3% of total market revenue. The region benefits from well-established healthcare infrastructure, extensive laboratory automation, strong research funding, and relatively rapid adoption of advanced diagnostic technologies.

The presence of major hospitals, reference laboratories, biotechnology companies, pharmaceutical organizations, and academic research institutions provides a strong customer base for ELISA analyzers. These organizations use immunoassay technologies across clinical diagnostics, drug discovery, biomarker research, and other life sciences applications.

Strong investment in biomedical research is another factor supporting regional demand. According to the National Institutes of Health, the agency funded approximately USD 37.8 billion for research projects in fiscal year 2024. Such investment supports biomedical and translational research and creates demand for laboratory instrumentation.

The U.S. also maintains a substantial research ecosystem. According to the National Science Foundation, the country spent approximately USD 940 billion on research and experimental development in 2023.

Continued investment in healthcare infrastructure, laboratory modernization, biotechnology, and biomedical research is expected to reinforce North America's leading position in the global ELISA analyzers market.

Technological Advancements Transforming the ELISA Analyzers Industry

Technological innovation is becoming an important competitive factor in the ELISA analyzers market. Manufacturers are developing fully automated systems with higher throughput, improved software capabilities, connectivity, and user-friendly interfaces.

Integration with laboratory information systems can enable more efficient transfer and management of testing data. Automated workflows can also support laboratories in processing increasing sample volumes while maintaining consistency and reducing turnaround times.

Compact and portable ELISA analyzers are gaining attention as smaller laboratories and decentralized testing facilities seek flexible diagnostic solutions. These systems can provide automation capabilities without requiring the infrastructure associated with larger laboratory platforms.

Manufacturers are also expanding assay menus and developing solutions for clinical diagnostics, research, pharmaceutical development, food testing, veterinary diagnostics, and environmental applications. Product versatility is therefore becoming increasingly important as companies seek to address a broader range of laboratory requirements.

Competitive Landscape

The global ELISA analyzers market includes major diagnostic and laboratory equipment companies competing on automation capabilities, throughput, assay compatibility, software integration, product reliability, service networks, and application coverage.

Leading companies include Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Danaher Corporation, Revvity, Inc., Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., Siemens Healthineers AG, Abbott Laboratories, bioMérieux SA, Tecan Group Ltd., Dynex Technologies, Inc., Awareness Technology, Inc., EUROIMMUN Medizinische Labordiagnostika AG, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Rayto Life and Analytical Sciences Co., Ltd., Robonik India Pvt. Ltd., HUMAN Gesellschaft für Biochemica und Diagnostica mbH, BMG LABTECH GmbH, BioTek Instruments, Inc., and Trinity Biotech plc.

Companies are focusing on automated workflow development, high-throughput processing, assay menu expansion, software connectivity, laboratory integration, and post-sales service. Strategic product development and improvements in automation are expected to remain central to competition as laboratories increasingly seek integrated diagnostic workflows.

Key Developments in ELISA Analyzers Market

In April 2024, Revvity introduced an automated workflow for its T-SPOT.TB test by integrating it with the Auto-Pure 2400 liquid handling platform. The solution was designed to reduce manual handling, improve laboratory workflow efficiency, and support medium- to high-throughput tuberculosis testing.

In February 2024, Revvity showcased the EnVision Nexus multimode microplate reader and other laboratory automation technologies at SLAS 2024. The technologies strengthened the company's portfolio for high-throughput assay development and laboratory research workflows.

In February 2024, Tecan introduced new laboratory automation solutions at SLAS 2024, including advanced liquid handling systems and digital workflow technologies designed to improve efficiency and productivity in research and diagnostic laboratories.

ELISA Analyzers Market Segmentation

Based on product type, the global ELISA analyzers market is segmented into bench-top ELISA analyzers, portable/handheld ELISA analyzers, automated ELISA workstations, and microplate readers. Automated ELISA workstations accounted for the largest share in 2025 because of their ability to integrate multiple testing steps and support high-volume laboratory workflows.

Based on processing mode, the market is divided into fully automated ELISA analyzers and semi-automated ELISA analyzers. Fully automated systems can perform multiple assay procedures with limited manual intervention, while semi-automated systems provide a balance between automation and operator involvement.

By application, the market covers clinical diagnostics, drug discovery and development, food and beverage testing, veterinary diagnostics, environmental testing, and research and academic laboratories.

Based on end user, the market is categorized into hospitals and diagnostic laboratories, pharmaceutical and biotechnology companies, academic and research institutes, and contract research organizations.

Geographically, the global ELISA analyzers market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Key countries covered include the U.S., Canada, Germany, U.K., France, Italy, Spain, the Netherlands, China, India, Japan, South Korea, Australia, ASEAN, Brazil, Mexico, Argentina, GCC countries, and South Africa.

ELISA Analyzers Market Outlook

The global ELISA analyzers market is expected to maintain steady growth through 2036 as laboratories increasingly prioritize automation, diagnostic accuracy, testing efficiency, and higher sample-processing capacity. The market is projected to expand from USD 0.8 billion in 2025 to USD 1.6 billion by 2036, advancing at a CAGR of 6.7% from 2026 to 2036.

The increasing burden of infectious and chronic diseases will continue to create demand for reliable immunoassay-based testing. At the same time, growing laboratory automation is encouraging healthcare providers and research organizations to replace manual procedures with integrated automated systems.

Automated ELISA workstations are expected to remain a major product segment because of their ability to handle high testing volumes while integrating sample preparation, assay processing, reading, and analysis. Expansion of diagnostic infrastructure in emerging economies is also likely to create significant opportunities as governments increase access to laboratory services.

North America is expected to remain a leading regional market due to its advanced healthcare infrastructure, established laboratory networks, strong biomedical research ecosystem, and high adoption of laboratory automation. Meanwhile, investments in healthcare and diagnostic infrastructure across emerging economies are expected to broaden the geographic customer base.

Technological developments involving higher throughput, LIS connectivity, compact systems, improved software integration, and expanded assay menus will continue to shape the competitive landscape. As laboratories increasingly seek faster turnaround times, standardized testing, and efficient workflows, demand for advanced ELISA analyzers is expected to remain strong over the forecast period.

Buy Full Report Now: https://www.transparencymarketresearch.com/checkout.php?rep_id=85919<ype=S

→Explore Latest Research Reports by Transparency Market Research:

Ligament Stabilizer Market

Spine Surgery Products Market

Ostomy Dressing Market

Asthma Spacers Market

Intragastric Balloons Market

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Media Contact: 

Abhishek Budholiya

Transparency Market Research Inc.

State Tower, 90 State Street, Suite 700,

Albany NY - 12207, United States

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com 

Sales Inquiries: sales@transparencymarketresearch.com

Media Inquiries: media@transparencymarketresearch.com